ND7001

ND7001 is a small molecule drug candidate that acts as a selective inhibitor of phosphodiesterase 2 (PDE2). It belongs to a new generation of psychoactive compounds and has been investigated primarily for its potential antidepressant and anxiolytic effects. The compound features a benzodiazepine ring structure, which is characteristic of drugs with tranquilizer properties. Mechanistically, ND7001 inhibits PDE2, thereby modulating cyclic nucleotide signaling pathways (cAMP and cGMP), which are implicated in mood regulation, learning, and memory processes. Preclinical studies have shown that ND7001 can enhance memory performance in animal models by increasing phosphorylation of CREB and VASP—downstream targets involved in synaptic plasticity. While it was initially developed as an antidepressant with anxiolytic activity, research also suggests potential utility for cognitive enhancement or treatment of diseases related to cognitive decline[1][2][4][5].